CN1077891C - 作为5-ht4或h3受体配位体有效的5-苯基-3-(哌啶-4-基)-1,3,4-噁二唑-2(3h)-酮衍生物 - Google Patents

作为5-ht4或h3受体配位体有效的5-苯基-3-(哌啶-4-基)-1,3,4-噁二唑-2(3h)-酮衍生物 Download PDF

Info

Publication number
CN1077891C
CN1077891C CN96198208A CN96198208A CN1077891C CN 1077891 C CN1077891 C CN 1077891C CN 96198208 A CN96198208 A CN 96198208A CN 96198208 A CN96198208 A CN 96198208A CN 1077891 C CN1077891 C CN 1077891C
Authority
CN
China
Prior art keywords
dihydro
compound
gram
perhaps
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96198208A
Other languages
English (en)
Chinese (zh)
Other versions
CN1202169A (zh
Inventor
S·杰哈姆
A·罗谢德
F·加利
A·纳德勒
A·索利纳
L·德克鲁兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of CN1202169A publication Critical patent/CN1202169A/zh
Application granted granted Critical
Publication of CN1077891C publication Critical patent/CN1077891C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN96198208A 1995-11-09 1996-11-05 作为5-ht4或h3受体配位体有效的5-苯基-3-(哌啶-4-基)-1,3,4-噁二唑-2(3h)-酮衍生物 Expired - Fee Related CN1077891C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR95/13253 1995-11-09
FR95/13252 1995-11-09
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR96/02663 1996-03-04
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
CN1202169A CN1202169A (zh) 1998-12-16
CN1077891C true CN1077891C (zh) 2002-01-16

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96198208A Expired - Fee Related CN1077891C (zh) 1995-11-09 1996-11-05 作为5-ht4或h3受体配位体有效的5-苯基-3-(哌啶-4-基)-1,3,4-噁二唑-2(3h)-酮衍生物

Country Status (29)

Country Link
US (1) US5929089A (OSRAM)
EP (1) EP0863897B1 (OSRAM)
JP (1) JP4263240B2 (OSRAM)
CN (1) CN1077891C (OSRAM)
AR (1) AR004708A1 (OSRAM)
AT (1) ATE181328T1 (OSRAM)
AU (1) AU707325B2 (OSRAM)
BG (1) BG63463B1 (OSRAM)
BR (1) BR9611311A (OSRAM)
CA (1) CA2236357C (OSRAM)
CO (1) CO4770968A1 (OSRAM)
CZ (1) CZ287268B6 (OSRAM)
DE (1) DE69602970T2 (OSRAM)
EE (1) EE03487B1 (OSRAM)
ES (1) ES2135934T3 (OSRAM)
GR (1) GR3030823T3 (OSRAM)
HU (1) HUP0001168A3 (OSRAM)
IL (1) IL124364A (OSRAM)
MX (1) MX9803696A (OSRAM)
NO (1) NO309606B1 (OSRAM)
NZ (1) NZ321626A (OSRAM)
PL (1) PL186204B1 (OSRAM)
RU (1) RU2167160C2 (OSRAM)
SI (1) SI0863897T1 (OSRAM)
SK (1) SK282335B6 (OSRAM)
TR (1) TR199800827T2 (OSRAM)
TW (1) TW371303B (OSRAM)
UA (1) UA50748C2 (OSRAM)
WO (1) WO1997017345A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
JP2002504896A (ja) * 1997-05-06 2002-02-12 サノフィ−サンテラボ ５−フェニル−１，３，４−オキサジアゾール−２（３ｈ）−オン誘導体およびそれらの５−ｈｔ４リガンドとしての使用
FR2763068B1 (fr) 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
DK1112106T3 (da) 1998-09-18 2005-12-12 Alcon Mfg Ltd Serotonerge 5HT2-agonister til behandling af glaukom
EP1173168A2 (en) * 1999-04-28 2002-01-23 Respiratorius AB Compound for use as a medicament for treatment of disorders involving bronchocontraction
JP2003501462A (ja) * 1999-06-15 2003-01-14 レスピラトリウス アクチボラゲット 受容体アゴニストおよびアンタゴニスト
DK1313721T3 (da) 2000-08-08 2006-06-26 Ortho Mcneil Pharm Inc Ikke-imidazol-aryloxyalkylaminer som H3-receptorligander
HUP0302893A3 (en) 2000-08-08 2006-04-28 Ortho Mcneil Pharm Inc Non-imidazole aryloxypiperidines and pharmaceutical compositions containing them and their use
AU2001281119A1 (en) * 2000-08-08 2002-02-18 Ortho-Mcneil Pharmaceutical, Inc. Bicyclic compounds as h3 receptor ligands
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
ATE450508T1 (de) * 2001-09-14 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
ATE479655T1 (de) 2001-09-14 2010-09-15 High Point Pharmaceuticals Llc Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
CA2469663A1 (en) 2001-12-14 2003-06-26 Alcon, Inc. Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
CA2569654C (en) 2004-06-15 2010-12-21 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
CA2614116A1 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
CN101321525B (zh) * 2005-12-01 2013-01-30 霍夫曼-拉罗奇有限公司 作为l-cpt1抑制剂的杂芳基取代的哌啶衍生物
SI2079732T1 (sl) 2006-05-29 2012-03-30 High Point Pharmaceuticals Llc benzodioksol il ciklopropilpiperazin il piridazin njegove soli in solvati in njegova uporaba kot antagonist histaminskega receptorja H
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
PL2758394T3 (pl) * 2011-09-19 2015-08-31 Suven Life Sciences Ltd Związki heteroarylowe jako ligandy receptora 5-HT4

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016072A1 (en) * 1992-02-06 1993-08-19 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055476A (en) * 1990-08-13 1991-10-08 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
WO1993003725A1 (en) * 1991-08-20 1993-03-04 Smithkline Beecham Plc 5-ht4 receptor antagonists
JP3294611B2 (ja) * 1991-09-12 2002-06-24 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ４レセプター・アンタゴニスト
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016072A1 (en) * 1992-02-06 1993-08-19 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists

Also Published As

Publication number Publication date
JP2000500125A (ja) 2000-01-11
EP0863897A1 (fr) 1998-09-16
HK1016165A1 (en) 1999-10-29
BG63463B1 (bg) 2002-02-28
NO982092D0 (no) 1998-05-07
ES2135934T3 (es) 1999-11-01
NO309606B1 (no) 2001-02-26
IL124364A (en) 2001-08-08
DE69602970T2 (de) 2000-01-20
AR004708A1 (es) 1999-03-10
CA2236357C (en) 2006-10-17
PL186204B1 (pl) 2003-11-28
SK59998A3 (en) 1998-11-04
CO4770968A1 (es) 1999-04-30
AU707325B2 (en) 1999-07-08
EP0863897B1 (fr) 1999-06-16
PL326671A1 (en) 1998-10-12
MX9803696A (es) 1998-09-30
US5929089A (en) 1999-07-27
NZ321626A (en) 1998-10-28
SI0863897T1 (en) 1999-10-31
CN1202169A (zh) 1998-12-16
UA50748C2 (uk) 2002-11-15
NO982092L (no) 1998-06-29
ATE181328T1 (de) 1999-07-15
SK282335B6 (sk) 2002-01-07
HUP0001168A3 (en) 2001-07-30
IL124364A0 (en) 1998-12-06
CA2236357A1 (en) 1997-05-15
DE69602970D1 (de) 1999-07-22
AU7500196A (en) 1997-05-29
BG102412A (en) 1999-08-31
RU2167160C2 (ru) 2001-05-20
BR9611311A (pt) 1999-06-29
CZ142198A3 (cs) 1998-08-12
EE03487B1 (et) 2001-08-15
TR199800827T2 (xx) 1999-02-22
EE9800155A (et) 1998-12-15
TW371303B (en) 1999-10-01
WO1997017345A1 (fr) 1997-05-15
HUP0001168A2 (hu) 2001-04-28
GR3030823T3 (en) 1999-11-30
JP4263240B2 (ja) 2009-05-13
CZ287268B6 (en) 2000-10-11

Similar Documents

Publication Publication Date Title
CN1077891C (zh) 作为5-ht4或h3受体配位体有效的5-苯基-3-(哌啶-4-基)-1,3,4-噁二唑-2(3h)-酮衍生物
CN1035615C (zh) 作为新的乙酰胆碱酯酶抑制剂的芳香杂环胺类的制备方法
CN1271355A (zh) 杂环化合物和以其为有效成分的抗肿瘤剂
CN1222521A (zh) 1,3,8－三氮杂螺[4,5]癸－4－酮衍生物
CN1027368C (zh) 新型取代的喹啉衍生物的制备方法
CN1045583A (zh) 四氢苯并咪唑衍生物
CN1023602C (zh) 制备抑制精神的3-哌嗪基苯并唑类衍生物的方法
CN1232520C (zh) 双环n－酰化的咪唑－3－胺和咪唑－5－胺的盐
CN86102349A (zh) 制备n-[(4-哌啶基)烷基]取代的双环稠合的唑与噻唑胺之方法
CN1069640C (zh) 噁唑烷酮衍生物,其制备方法及含它们的药物组合物
CN1031262C (zh) 环取代的2-氨基-1，2，3，4-四氢化萘和3-氨基苯并二氢吡喃
CN1114957A (zh) 新(硫代)环烷基[b]吲哚化合物及制法和药物组合物
CN100338074C (zh) 杂环化合物和以其为有效成分的脑机能改善剂
CN1260226C (zh) 用作mGluR1拮抗剂的四氢－(苯并或噻吩并)－氮杂䓬－吡嗪和三嗪衍生物
CN1166629C (zh) 新型苯磺酰胺化合物、其制备方法和含有其的药物组合物
CN1249059C (zh) 新型哌啶羧酸酰胺衍生物、其制备方法以及含有它们的药物组合物
CN1184478A (zh) 噻唑衍生物
CN1140526C (zh) 作为d2和d3型多巴胺和5ht1a和5ht2型含血清素受体配位体的8－氮杂二环[3.2.1]辛烷－3－甲胺衍生物
CN1017901B (zh) 抗精神病药稠环吡啶基哌嗪衍生物的制备方法
CN1155570C (zh) 新的氰基-吲哚5-羟色胺再摄取抑制剂化合物、其制备方法和含有它们的药物组合物
CN1117729A (zh) 吗啉衍生物
CN1135215A (zh) 咪唑啉酮衍生物、其酸的加成盐及老年痴呆症的治疗药物
CN1345317A (zh) (1－苯甲酰甲基－3－苯基－3－哌啶基乙基)哌啶衍生物,制备它们的方法以及包含它们的药物组合物
CN1344717A (zh) 具有镇痛作用的新型哌嗪季铵盐类化合物
CN1823054A (zh) 咪唑衍生物ⅲ

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SANOFI - AVENTIS

Free format text: FORMER NAME OR ADDRESS: ST. SANOFI - SYNTHELABO CORPORATION

CP01 Change in the name or title of a patent holder

Address after: Paris France

Patentee after: SANOFI-AVENTIS

Address before: Paris France

Patentee before: Sanofi-Synthelabo

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20020116

Termination date: 20131105